SCNI (Scinai) רווחיות מכירות לפי רווח גולמי

The restructuring of production capacities and significant fixed costs are hindering the operational efficiency of Scinai Immunotherapeutics (SCNI). The company's revenues rely on the development of nanotechnological antibodies to combat COVID-19 and influenza. Geopolitical barriers are obstructing international trials, which is reflected in the gross profit margin. The current 0.00 metric reflects margin dynamics under the influence of Fed policy.
פילוחי מדדים מקיפים ואנליטיקה עבור Scinai Immunotherapeutics (SCNI)

Proprietary nanobody development and high barriers to entry in the biotech sector provide Scinai Immunotherapeutics (SCNI) with a unique market position. By analyzing the gross margin vector, an investor can see the portion of revenue remaining after covering direct production costs. This metric measures the business's operational efficiency, allowing for the timely identification of profitability compression and a critical decline in the core product's profitability.